UnitedHealth (UNH) 10-Q 2 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	6 Months Ended
	Jun. 30, 2023	Jul. 31, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	1-10864
Entitiy Registrant Name	UnitedHealth Group Incorporated
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1321939
Entity Address, Address Line One	UnitedHealth Group Center
Entity Address, Address Line Two	9900 Bren Road East
Entity Address, City or Town	Minnetonka,
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55343
City Area Code	952
Local Phone Number	936-1300
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	UNH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entitiy Central Index Key	0000731766
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		926,305,139

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 41,813	$ 23,365
Short-term investments	4,466	4,546
Accounts receivable, net	17,952	17,681
Other current receivables, net	16,131	12,769
Assets under management	3,623	4,087
Prepaid expenses and other current assets	5,884	6,621
Total current assets	89,869	69,069
Long-term investments	45,988	43,728
Property, equipment and capitalized software, net	10,926	10,128
Goodwill	101,669	93,352
Other intangible assets, net	15,643	14,401
Other assets	16,069	15,027
Total assets	280,164	245,705
Current liabilities:
Medical costs payable	31,947	29,056
Accounts payable and accrued liabilities	29,516	27,715
Short-term borrowings and current maturities of long-term debt	6,321	3,110
Unearned revenues	14,852	3,075
Other current liabilities	30,345	26,281
Total current liabilities	112,981	89,237
Long-term debt, less current maturities	59,268	54,513
Deferred income taxes	2,498	2,769
Other liabilities	13,261	12,839
Total liabilities	188,008	159,358
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests	4,788	4,897
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.01 par value - 3,000 shares authorized; 927 and 934 issued and outstanding	9	9
Retained earnings	89,994	86,156
Accumulated other comprehensive loss	(7,650)	(8,393)
Nonredeemable noncontrolling interests	5,015	3,678
Total equity	87,368	81,450
Total liabilities, redeemable noncontrolling interests and equity	$ 280,164	$ 245,705
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10	10
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000	3,000
Common stock, shares issued	927	934
Common stock, shares outstanding	927	934

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues:
Premiums	$ 72,474	$ 63,896	$ 145,260	$ 127,966
Investment and other income	1,115	295	1,913	662
Total revenues	92,903	80,332	184,834	160,481
Operating costs:
Medical costs	60,268	52,093	120,113	104,616
Operating costs	13,809	11,709	27,434	23,110
Cost of products sold	9,748	8,596	19,153	17,083
Depreciation and amortization	1,021	802	1,991	1,590
Total operating costs	84,846	73,200	168,691	146,399
Earnings from operations	8,057	7,132	16,143	14,082
Interest expense	(828)	(467)	(1,582)	(900)
Earnings before income taxes	7,229	6,665	14,561	13,182
Provision for income taxes	(1,572)	(1,466)	(3,130)	(2,835)
Net earnings	5,657	5,199	11,431	10,347
Earnings attributable to noncontrolling interests	(183)	(129)	(346)	(250)
Net earnings attributable to UnitedHealth Group common shareholders	$ 5,474	$ 5,070	$ 11,085	$ 10,097
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic	$ 5.89	$ 5.41	$ 11.91	$ 10.75
Diluted	$ 5.82	$ 5.34	$ 11.77	$ 10.61
Basic weighted-average number of common shares outstanding	930	937	931	939
Dilutive effect of common share equivalents	10	13	11	13
Diluted weighted-average number of common shares outstanding	940	950	942	952
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents	7	3	6	3
Products
Revenue from Products and Services	$ 10,651	$ 9,496	$ 20,918	$ 18,836
Services
Revenue from Products and Services	$ 8,663	$ 6,645	$ 16,743	$ 13,017

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Net earnings	$ 5,657	$ 5,199	$ 11,431	$ 10,347
Other comprehensive (loss) income:
Gross unrealized (losses) gains on investment securities during the period	(431)	(1,331)	209	(3,354)
Income tax effect	99	304	(48)	769
Total unrealized (losses) gains, net of tax	(332)	(1,027)	161	(2,585)
Gross reclassification adjustment for net realized gains included in net earnings	(47)	(1)	(34)	(4)
Income tax effect	11	0	8	1
Total reclassification adjustment, net of tax	(36)	(1)	(26)	(3)
Total foreign currency translation gains (losses)	267	(676)	608	242
Other comprehensive (loss) income	(101)	(1,704)	743	(2,346)
Comprehensive income	5,556	3,495	12,174	8,001
Comprehensive income attributable to noncontrolling interests	(183)	(129)	(346)	(250)
Comprehensive income attributable to UnitedHealth Group common shareholders	$ 5,373	$ 3,366	$ 11,828	$ 7,751

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Net Unrealized (Losses) Gains on Investments [Member]	Foreign Currency Translation (Losses) Gains [Member]	Nonredeemable Noncontrolling Interests [Member]
Balance at Dec. 31, 2021	$ 75,045	$ 10	$ 0	$ 77,134	$ 423	$ (5,807)	$ 3,285
Balance (in shares) at Dec. 31, 2021		941
Net earnings attributable to UnitedHealth Group common shareholders	10,097			10,097
Net earnings attributable to nonredeemable noncontrolling interest							182
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	10,279
Other comprehensive (loss) income	(2,346)				(2,588)	242
Issuances of common stock, and related tax effects (in shares)		4
Issuances of common stock, and related tax effects	507	$ 0	507
Share-based compensation	476		476
Common share repurchases (in shares)		(10)
Common share repurchases	(5,000)	$ 0	(1,217)	(3,783)
Cash dividends paid on common shares	(2,908)			(2,908)
Redeemable noncontrolling interests fair value and other adjustments	234		234
Acquisition and other adjustments of nonredeemable noncontrolling interests	103						103
Distribution to nonredeemable noncontrolling interests	(185)						(185)
Balance at Jun. 30, 2022	$ 76,205	$ 10	0	80,540	(2,165)	(5,565)	3,385
Balance (in shares) at Jun. 30, 2022		935
Common Stock, Dividends, Per Share, Cash Paid	$ 3.10
Balance at Mar. 31, 2022	$ 76,128	$ 10	0	78,782	(1,137)	(4,889)	3,362
Balance (in shares) at Mar. 31, 2022		939
Net earnings attributable to UnitedHealth Group common shareholders	5,070			5,070
Net earnings attributable to nonredeemable noncontrolling interest							94
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	5,164
Other comprehensive (loss) income	(1,704)				(1,028)	(676)
Issuances of common stock, and related tax effects (in shares)		1
Issuances of common stock, and related tax effects	174	$ 0	174
Share-based compensation	194		194
Common share repurchases (in shares)		(5)
Common share repurchases	(2,500)	$ 0	(733)	(1,767)
Cash dividends paid on common shares	(1,545)			(1,545)
Redeemable noncontrolling interests fair value and other adjustments	365		365
Acquisition and other adjustments of nonredeemable noncontrolling interests	12						12
Distribution to nonredeemable noncontrolling interests	(83)						(83)
Balance at Jun. 30, 2022	$ 76,205	$ 10	0	80,540	(2,165)	(5,565)	3,385
Balance (in shares) at Jun. 30, 2022		935
Common Stock, Dividends, Per Share, Cash Paid	$ 1.65
Balance at Dec. 31, 2022	$ 81,450	$ 9	0	86,156	(2,778)	(5,615)	3,678
Balance (in shares) at Dec. 31, 2022	934	934
Net earnings attributable to UnitedHealth Group common shareholders	$ 11,085			11,085
Net earnings attributable to nonredeemable noncontrolling interest							252
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	11,337
Other comprehensive (loss) income	743				135	608
Issuances of common stock, and related tax effects (in shares)		3
Issuances of common stock, and related tax effects	568	$ 0	568
Share-based compensation	598		598
Common share repurchases (in shares)		(10)
Common share repurchases	(5,038)	$ 0	(1,075)	(3,963)
Cash dividends paid on common shares	(3,284)			(3,284)
Redeemable noncontrolling interests fair value and other adjustments	(91)		(91)
Acquisition and other adjustments of nonredeemable noncontrolling interests	1,297						1,297
Distribution to nonredeemable noncontrolling interests	(212)						(212)
Balance at Jun. 30, 2023	$ 87,368	$ 9	0	89,994	(2,643)	(5,007)	5,015
Balance (in shares) at Jun. 30, 2023	927	927
Common Stock, Dividends, Per Share, Cash Paid	$ 3.53
Balance at Mar. 31, 2023	$ 85,821	$ 9	0	88,852	(2,275)	(5,274)	4,509
Balance (in shares) at Mar. 31, 2023		932
Net earnings attributable to UnitedHealth Group common shareholders	5,474			5,474
Net earnings attributable to nonredeemable noncontrolling interest							139
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest	5,613
Other comprehensive (loss) income	(101)				(368)	267
Issuances of common stock, and related tax effects (in shares)		1
Issuances of common stock, and related tax effects	218	$ 0	218
Share-based compensation	232		232
Common share repurchases (in shares)		(6)
Common share repurchases	(3,027)	$ 0	(442)	(2,585)
Cash dividends paid on common shares	(1,747)			(1,747)
Redeemable noncontrolling interests fair value and other adjustments	(8)		(8)
Acquisition and other adjustments of nonredeemable noncontrolling interests	478						478
Distribution to nonredeemable noncontrolling interests	(111)						(111)
Balance at Jun. 30, 2023	$ 87,368	$ 9	$ 0	$ 89,994	$ (2,643)	$ (5,007)	$ 5,015
Balance (in shares) at Jun. 30, 2023	927	927
Common Stock, Dividends, Per Share, Cash Paid	$ 1.88

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Operating activities
Net earnings	$ 11,431	$ 10,347
Noncash items:
Depreciation and amortization	1,991	1,590
Deferred income taxes	(482)	(15)
Share-based compensation	604	504
Other, net	(91)	215
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:
Accounts receivable	197	(4,204)
Other assets	(2,001)	(643)
Medical costs payable	2,408	4,029
Accounts payable and other liabilities	1,547	807
Unearned revenues	11,755	(440)
Cash flows from operating activities	27,359	12,190
Investing activities
Purchases of investments	(9,225)	(8,903)
Sales of investments	3,188	2,348
Maturities of investments	4,463	3,189
Cash paid for acquisitions, net of cash assumed	(8,161)	(7,150)
Purchases of property, equipment and capitalized software	(1,589)	(1,212)
Other, net	(424)	(532)
Cash flows used for investing activities	(11,748)	(12,260)
Financing activities
Common share repurchases	(5,000)	(5,000)
Cash dividends paid	(3,284)	(2,908)
Proceeds from common stock issuances	628	756
Repayments of long-term debt	(2,125)	(1,100)
Proceeds from short-term borrowings, net	3,426	1,340
Proceeds from issuance of long-term debt	6,394	5,922
Customer funds administered	4,069	5,786
Other, net	(1,377)	(1,546)
Cash flows from financing activities	2,731	3,250
Effect of exchange rate changes on cash and cash equivalents	106	57
Increase in cash and cash equivalents	18,448	3,237
Cash and cash equivalents, beginning of period	23,365	21,375
Cash and cash equivalents, end of period	$ 41,813	$ 24,612

Basis of Presentation (Notes)

Basis of Presentation (Notes)	6 Months Ended
	Jun. 30, 2023
Basis of Presentation and Significant Accounting Policies [Text Block]	Basis of Presentation UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve. The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC (2022 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly. Use of Estimates These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted. Revenues - Products and Services

Investments (Notes)

Investments (Notes)	6 Months Ended
	Jun. 30, 2023
Investments [Abstract]
Investments [Text Block]	Investments A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair June 30, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,990 $ — $ (283) $ 4,707 State and municipal obligations 7,334 10 (427) 6,917 Corporate obligations 23,582 11 (1,643) 21,950 U.S. agency mortgage-backed securities 8,504 5 (799) 7,710 Non-U.S. agency mortgage-backed securities 3,148 — (304) 2,844 Total debt securities - available-for-sale 47,558 26 (3,456) 44,128 Debt securities - held-to-maturity: U.S. government and agency obligations 466 — (11) 455 State and municipal obligations 28 — (3) 25 Corporate obligations 246 — — 246 Total debt securities - held-to-maturity 740 — (14) 726 Total debt securities $ 48,298 $ 26 $ (3,470) $ 44,854 December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,093 $ 1 $ (285) $ 3,809 State and municipal obligations 7,702 25 (479) 7,248 Corporate obligations 23,675 17 (1,798) 21,894 U.S. agency mortgage-backed securities 7,379 15 (808) 6,586 Non-U.S. agency mortgage-backed securities 3,077 1 (294) 2,784 Total debt securities - available-for-sale 45,926 59 (3,664) 42,321 Debt securities - held-to-maturity: U.S. government and agency obligations 578 — (14) 564 State and municipal obligations 29 — (3) 26 Corporate obligations 89 — — 89 Total debt securities - held-to-maturity 696 — (17) 679 Total debt securities $ 46,622 $ 59 $ (3,681) $ 43,000 The Company held $4.2 billion and $3.7 billion of equity securities as of June 30, 2023 and December 31, 2022, respectively. The Company’s investments in equity securities primarily consist of employee savings plan related investments, venture investments and shares of Brazilian real denominated fixed-income funds with readily determinable fair values. Additionally, the Company’s investments included $1.4 billion and $1.5 billion of equity method investments in operating businesses in the health care sector as of June 30, 2023 and December 31, 2022, respectively. The allowance for credit losses on held-to-maturity securities at June 30, 2023 and December 31, 2022 was not material. The amortized cost and fair value of debt securities as of June 30, 2023, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 4,646 $ 4,613 $ 466 $ 461 Due after one year through five years 14,748 13,935 225 219 Due after five years through ten years 11,332 10,206 31 30 Due after ten years 5,180 4,820 18 16 U.S. agency mortgage-backed securities 8,504 7,710 — — Non-U.S. agency mortgage-backed securities 3,148 2,844 — — Total debt securities $ 47,558 $ 44,128 $ 740 $ 726 The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross June 30, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 2,300 $ (28) $ 1,902 $ (255) $ 4,202 $ (283) State and municipal obligations 2,769 (46) 3,324 (381) 6,093 (427) Corporate obligations 6,346 (122) 13,974 (1,521) 20,320 (1,643) U.S. agency mortgage-backed securities 3,111 (79) 4,314 (720) 7,425 (799) Non-U.S. agency mortgage-backed securities 577 (15) 2,239 (289) 2,816 (304) Total debt securities - available-for-sale $ 15,103 $ (290) $ 25,753 $ (3,166) $ 40,856 $ (3,456) December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 2,007 $ (96) $ 1,290 $ (189) $ 3,297 $ (285) State and municipal obligations 4,630 (288) 1,178 (191) 5,808 (479) Corporate obligations 13,003 (893) 6,637 (905) 19,640 (1,798) U.S. agency mortgage-backed securities 3,561 (345) 2,239 (463) 5,800 (808) Non-U.S. agency mortgage-backed securities 1,698 (128) 976 (166) 2,674 (294) Total debt securities - available-for-sale $ 24,899 $ (1,750) $ 12,320 $ (1,914) $ 37,219 $ (3,664) The Company’s unrealized losses from debt securities as of June 30, 2023 were generated from approximately 35,000 positions out of a total of 41,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of June 30, 2023, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at June 30, 2023 and December 31, 2022 was not material.

Fair Value (Notes)

Fair Value (Notes)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value [Text Block]	Fair Value Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K. The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total June 30, 2023 Cash and cash equivalents $ 41,763 $ 50 $ — $ 41,813 Debt securities - available-for-sale: U.S. government and agency obligations 4,318 389 — 4,707 State and municipal obligations — 6,917 — 6,917 Corporate obligations 36 21,732 182 21,950 U.S. agency mortgage-backed securities — 7,710 — 7,710 Non-U.S. agency mortgage-backed securities — 2,844 — 2,844 Total debt securities - available-for-sale 4,354 39,592 182 44,128 Equity securities 2,270 37 70 2,377 Assets under management 1,332 2,190 101 3,623 Total assets at fair value $ 49,719 $ 41,869 $ 353 $ 91,941 Percentage of total assets at fair value 54 % 45 % 1 % 100 % December 31, 2022 Cash and cash equivalents $ 23,202 $ 163 $ — $ 23,365 Debt securities - available-for-sale: U.S. government and agency obligations 3,505 304 — 3,809 State and municipal obligations — 7,248 — 7,248 Corporate obligations 7 21,695 192 21,894 U.S. agency mortgage-backed securities — 6,586 — 6,586 Non-U.S. agency mortgage-backed securities — 2,784 — 2,784 Total debt securities - available-for-sale 3,512 38,617 192 42,321 Equity securities 2,043 35 70 2,148 Assets under management 1,788 2,203 96 4,087 Total assets at fair value $ 30,545 $ 41,018 $ 358 $ 71,921 Percentage of total assets at fair value 42 % 57 % 1 % 100 % There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2023 or 2022. The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value June 30, 2023 Debt securities - held-to-maturity $ 651 $ 75 $ — $ 726 $ 740 Long-term debt and other financing obligations $ — $ 58,644 $ — $ 58,644 $ 61,217 December 31, 2022 Debt securities - held-to-maturity $ 577 $ 102 $ — $ 679 $ 696 Long-term debt and other financing obligations $ — $ 53,626 $ — $ 53,626 $ 56,823 Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the six months ended June 30, 2023 or 2022.

Medical Costs Payable (Notes)

Medical Costs Payable (Notes)	6 Months Ended
	Jun. 30, 2023
Insurance [Abstract]
Short-Duration Insurance and Deposit Contracts	Medical Costs Payable The following table shows the components of the change in medical costs payable for the six months ended June 30: (in millions) 2023 2022 Medical costs payable, beginning of period $ 29,056 $ 24,483 Acquisitions 1 171 Reported medical costs: Current year 120,773 104,936 Prior years (660) (320) Total reported medical costs 120,113 104,616 Medical payments: Payments for current year (91,621) (78,937) Payments for prior years (25,602) (21,355) Total medical payments (117,223) (100,292) Medical costs payable, end of period $ 31,947 $ 28,978

Short-Term Borrowings and Long-

Short-Term Borrowings and Long-Term Debt (Notes)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt Disclosure	Short-Term Borrowings and Long-Term Debt In March 2023, the Company issued $6.5 billion of senior unsecured notes consisting of the following: (in millions, except percentages) Par Value 4.250% notes due January 2029 $ 1,250 4.500% notes due April 2033 1,500 5.050% notes due April 2053 2,000 5.200% notes due April 2063 1,750 As of June 30, 2023, the Company had $4.4 billion of commercial paper outstanding, with a weighted-average annual interest rate of 5.1%. For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K.

Dividends (Notes)

Dividends (Notes)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity Note Disclosure	Dividends In June 2023, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $7.52 compared to $6.60 per share, which the Company had paid since June 2022. Declaration and payment of future quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions change. The following table provides details of the Company’s dividend payments during the six months ended June 30, 2023: Payment Date Amount per Share Total Amount Paid (in millions) March 21 $ 1.65 $ 1,537 June 27 1.88 1,747

Commitments and Contingencies (

Commitments and Contingencies (Notes)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Commitments and Contingencies Pending Acquisitions As of June 30, 2023, the Company has entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions. The total anticipated consideration required for these acquisitions, excluding the payoff of acquired indebtedness, is approximately $5 billion. Legal Matters The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices. The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred. Government Investigations, Audits and Reviews The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities. Similarly, our international businesses are also subject to investigations, audits and reviews by applicable foreign governments, including South American and other non-U.S. governmental authorities. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans. On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.

Business Combinations (Notes)

Business Combinations (Notes)	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Business Combination Disclosure	Business Combinations During the six months ended June 30, 2023, the Company completed several business combinations for total consideration of $8.2 billion. Acquired assets (liabilities) at acquisition date were: (in millions) Cash and cash equivalents $ 104 Accounts receivable and other current assets 550 Property, equipment and other long-term assets 542 Other intangible assets 1,795 Total identifiable assets acquired 2,991 Medical costs payable (1) Accounts payable and other current liabilities (473) Other long-term liabilities (617) Total identifiable liabilities acquired (1,091) Total net identifiable assets 1,900 Goodwill 7,734 Redeemable noncontrolling interests (113) Nonredeemable noncontrolling interests (1,297) Net assets acquired $ 8,224 The majority of goodwill is not deductible for income tax purposes. The preliminary purchase price allocations for the various business combinations are subject to adjustment as valuation analyses, primarily related to intangible assets and contingent liabilities, are finalized. The acquisition date fair values and weighted-average useful lives assigned to intangible assets were: (in millions, except years) Fair Value Weighted-Average Useful Life Acquired finite-lived intangible assets: Customer-related $ 223 12 years Trademarks and technology 171 5 years Other 38 6 years Total acquired finite-lived intangible assets 432 9 years Total acquired indefinite-lived intangible assets - operating licenses and certificates 1,363 Total acquired intangible assets $ 1,795 The results of operations and financial condition of acquired entities have been included in the Company’s consolidated results and the results of the corresponding operating segment as of the date of acquisition. Through June 30, 2023, acquired entities impact on revenues and net earnings was not material. Unaudited pro forma revenues and net earnings for the six months ended June 30, 2023 and 2022, as if the business combinations had occurred on January 1, 2022, were immaterial for both periods.

Segment Financial Information (

Segment Financial Information (Notes)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Reporting Disclosure	Segment Financial Information The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2022 10-K. Total assets at Optum Health increased to $80.8 billion as of June 30, 2023 compared to $69.0 billion as of December 31, 2022, primarily due to goodwill from business combinations of $7.0 billion. The following tables present reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated Three Months Ended June 30, 2023 Revenues - unaffiliated customers: Premiums $ 67,047 $ 5,427 $ — $ — $ — $ 5,427 $ — $ 72,474 Products — 51 39 10,561 — 10,651 — 10,651 Services 2,584 3,541 1,995 543 — 6,079 — 8,663 Total revenues - unaffiliated customers 69,631 9,019 2,034 11,104 — 22,157 — 91,788 Total revenues - affiliated customers — 14,454 2,615 17,496 (893) 33,672 (33,672) — Investment and other income 600 444 25 46 — 515 — 1,115 Total revenues $ 70,231 $ 23,917 $ 4,674 $ 28,646 $ (893) $ 56,344 $ (33,672) $ 92,903 Earnings from operations $ 4,358 $ 1,525 $ 968 $ 1,206 $ — $ 3,699 $ — $ 8,057 Interest expense — — — — — — (828) (828) Earnings before income taxes $ 4,358 $ 1,525 $ 968 $ 1,206 $ — $ 3,699 $ (828) $ 7,229 Three Months Ended June 30, 2022 Revenues - unaffiliated customers: Premiums $ 59,368 $ 4,528 $ — $ — $ — $ 4,528 $ — $ 63,896 Products — 6 58 9,432 — 9,496 — 9,496 Services 2,542 2,740 1,034 329 — 4,103 — 6,645 Total revenues - unaffiliated customers 61,910 7,274 1,092 9,761 — 18,127 — 80,037 Total revenues - affiliated customers — 10,224 2,181 15,038 (588) 26,855 (26,855) — Investment and other income 195 85 9 6 — 100 — 295 Total revenues $ 62,105 $ 17,583 $ 3,282 $ 24,805 $ (588) $ 45,082 $ (26,855) $ 80,332 Earnings from operations $ 3,850 $ 1,399 $ 839 $ 1,044 $ — $ 3,282 $ — $ 7,132 Interest expense — — — — — — (467) (467) Earnings before income taxes $ 3,850 $ 1,399 $ 839 $ 1,044 $ — $ 3,282 $ (467) $ 6,665 Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated Six Months Ended June 30, 2023 Revenues - unaffiliated customers: Premiums $ 134,505 $ 10,755 $ — $ — $ — $ 10,755 $ — $ 145,260 Products — 95 79 20,744 — 20,918 — 20,918 Services 5,139 6,630 3,921 1,053 — 11,604 — 16,743 Total revenues - unaffiliated customers 139,644 17,480 4,000 21,797 — 43,277 — 182,921 Total revenues - affiliated customers — 28,720 5,125 34,175 (1,752) 66,268 (66,268) — Investment and other income 1,055 721 45 92 — 858 — 1,913 Total revenues $ 140,699 $ 46,921 $ 9,170 $ 56,064 $ (1,752) $ 110,403 $ (66,268) $ 184,834 Earnings from operations $ 8,701 $ 3,301 $ 1,875 $ 2,266 $ — $ 7,442 $ — $ 16,143 Interest expense — — — — — — (1,582) (1,582) Earnings before income taxes $ 8,701 $ 3,301 $ 1,875 $ 2,266 $ — $ 7,442 $ (1,582) $ 14,561 Six Months Ended June 30, 2022 Revenues - unaffiliated customers: Premiums $ 119,305 $ 8,661 $ — $ — $ — $ 8,661 $ — $ 127,966 Products — 12 98 18,726 — 18,836 — 18,836 Services 5,057 5,298 2,008 654 — 7,960 — 13,017 Total revenues - unaffiliated customers 124,362 13,971 2,106 19,380 — 35,457 — 159,819 Total revenues - affiliated customers — 20,053 4,319 29,329 (1,141) 52,560 (52,560) — Investment and other income 338 241 76 7 — 324 — 662 Total revenues $ 124,700 $ 34,265 $ 6,501 $ 48,716 $ (1,141) $ 88,341 $ (52,560) $ 160,481 Earnings from operations $ 7,648 $ 2,765 $ 1,686 $ 1,983 $ — $ 6,434 $ — $ 14,082 Interest expense — — — — — — (900) (900) Earnings before income taxes $ 7,648 $ 2,765 $ 1,686 $ 1,983 $ — $ 6,434 $ (900) $ 13,182

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Pay vs Performance Disclosure
Net earnings attributable to UnitedHealth Group common shareholders	$ 5,474	$ 5,070	$ 11,085	$ 10,097

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2023
Basis of presentation [Abstract]
Basis of Accounting, Policy [Policy Text Block]	The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC (2022 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates, Policy [Policy Text Block]	These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenue [Policy Text Block]	As of June 30, 2023 and December 31, 2022, accounts receivable related to products and services were $7.7 billion and $7.1 billion, respectively. As of June 30, 2023, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $12.2 billion, of which approximately half is expected to be recognized in the next three years.

Investments (Policies)

Investments (Policies)	6 Months Ended
	Jun. 30, 2023
Investments [Abstract]
Investment, Policy [Policy Text Block]	At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of June 30, 2023, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2023
Short-Term and Long-Term Investments [Table Text Block]	A summary of debt securities by major security type is as follows: (in millions) Amortized Gross Gross Fair June 30, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,990 $ — $ (283) $ 4,707 State and municipal obligations 7,334 10 (427) 6,917 Corporate obligations 23,582 11 (1,643) 21,950 U.S. agency mortgage-backed securities 8,504 5 (799) 7,710 Non-U.S. agency mortgage-backed securities 3,148 — (304) 2,844 Total debt securities - available-for-sale 47,558 26 (3,456) 44,128 Debt securities - held-to-maturity: U.S. government and agency obligations 466 — (11) 455 State and municipal obligations 28 — (3) 25 Corporate obligations 246 — — 246 Total debt securities - held-to-maturity 740 — (14) 726 Total debt securities $ 48,298 $ 26 $ (3,470) $ 44,854 December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 4,093 $ 1 $ (285) $ 3,809 State and municipal obligations 7,702 25 (479) 7,248 Corporate obligations 23,675 17 (1,798) 21,894 U.S. agency mortgage-backed securities 7,379 15 (808) 6,586 Non-U.S. agency mortgage-backed securities 3,077 1 (294) 2,784 Total debt securities - available-for-sale 45,926 59 (3,664) 42,321 Debt securities - held-to-maturity: U.S. government and agency obligations 578 — (14) 564 State and municipal obligations 29 — (3) 26 Corporate obligations 89 — — 89 Total debt securities - held-to-maturity 696 — (17) 679 Total debt securities $ 46,622 $ 59 $ (3,681) $ 43,000
Investments by Contractual Maturity [Table Text Block]	The amortized cost and fair value of debt securities as of June 30, 2023, by contractual maturity, were as follows: Available-for-Sale Held-to-Maturity (in millions) Amortized Fair Amortized Fair Due in one year or less $ 4,646 $ 4,613 $ 466 $ 461 Due after one year through five years 14,748 13,935 225 219 Due after five years through ten years 11,332 10,206 31 30 Due after ten years 5,180 4,820 18 16 U.S. agency mortgage-backed securities 8,504 7,710 — — Non-U.S. agency mortgage-backed securities 3,148 2,844 — — Total debt securities $ 47,558 $ 44,128 $ 740 $ 726
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value	The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows: Less Than 12 Months 12 Months or Greater Total (in millions) Fair Gross Fair Gross Fair Gross June 30, 2023 Debt securities - available-for-sale: U.S. government and agency obligations $ 2,300 $ (28) $ 1,902 $ (255) $ 4,202 $ (283) State and municipal obligations 2,769 (46) 3,324 (381) 6,093 (427) Corporate obligations 6,346 (122) 13,974 (1,521) 20,320 (1,643) U.S. agency mortgage-backed securities 3,111 (79) 4,314 (720) 7,425 (799) Non-U.S. agency mortgage-backed securities 577 (15) 2,239 (289) 2,816 (304) Total debt securities - available-for-sale $ 15,103 $ (290) $ 25,753 $ (3,166) $ 40,856 $ (3,456) December 31, 2022 Debt securities - available-for-sale: U.S. government and agency obligations $ 2,007 $ (96) $ 1,290 $ (189) $ 3,297 $ (285) State and municipal obligations 4,630 (288) 1,178 (191) 5,808 (479) Corporate obligations 13,003 (893) 6,637 (905) 19,640 (1,798) U.S. agency mortgage-backed securities 3,561 (345) 2,239 (463) 5,800 (808) Non-U.S. agency mortgage-backed securities 1,698 (128) 976 (166) 2,674 (294) Total debt securities - available-for-sale $ 24,899 $ (1,750) $ 12,320 $ (1,914) $ 37,219 $ (3,664)

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block]	The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total June 30, 2023 Cash and cash equivalents $ 41,763 $ 50 $ — $ 41,813 Debt securities - available-for-sale: U.S. government and agency obligations 4,318 389 — 4,707 State and municipal obligations — 6,917 — 6,917 Corporate obligations 36 21,732 182 21,950 U.S. agency mortgage-backed securities — 7,710 — 7,710 Non-U.S. agency mortgage-backed securities — 2,844 — 2,844 Total debt securities - available-for-sale 4,354 39,592 182 44,128 Equity securities 2,270 37 70 2,377 Assets under management 1,332 2,190 101 3,623 Total assets at fair value $ 49,719 $ 41,869 $ 353 $ 91,941 Percentage of total assets at fair value 54 % 45 % 1 % 100 % December 31, 2022 Cash and cash equivalents $ 23,202 $ 163 $ — $ 23,365 Debt securities - available-for-sale: U.S. government and agency obligations 3,505 304 — 3,809 State and municipal obligations — 7,248 — 7,248 Corporate obligations 7 21,695 192 21,894 U.S. agency mortgage-backed securities — 6,586 — 6,586 Non-U.S. agency mortgage-backed securities — 2,784 — 2,784 Total debt securities - available-for-sale 3,512 38,617 192 42,321 Equity securities 2,043 35 70 2,148 Assets under management 1,788 2,203 96 4,087 Total assets at fair value $ 30,545 $ 41,018 $ 358 $ 71,921 Percentage of total assets at fair value 42 % 57 % 1 % 100 %
Fair Value Measurements, Nonrecurring [Table Text Block]	The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets: (in millions) Quoted Prices Other Unobservable Total Total Carrying Value June 30, 2023 Debt securities - held-to-maturity $ 651 $ 75 $ — $ 726 $ 740 Long-term debt and other financing obligations $ — $ 58,644 $ — $ 58,644 $ 61,217 December 31, 2022 Debt securities - held-to-maturity $ 577 $ 102 $ — $ 679 $ 696 Long-term debt and other financing obligations $ — $ 53,626 $ — $ 53,626 $ 56,823

Medical Costs Payable (Tables)

Medical Costs Payable (Tables)	6 Months Ended
	Jun. 30, 2023
Insurance [Abstract]
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	The following table shows the components of the change in medical costs payable for the six months ended June 30: (in millions) 2023 2022 Medical costs payable, beginning of period $ 29,056 $ 24,483 Acquisitions 1 171 Reported medical costs: Current year 120,773 104,936 Prior years (660) (320) Total reported medical costs 120,113 104,616 Medical payments: Payments for current year (91,621) (78,937) Payments for prior years (25,602) (21,355) Total medical payments (117,223) (100,292) Medical costs payable, end of period $ 31,947 $ 28,978

Short-Term Borrowings and Lon_2

Short-Term Borrowings and Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Instrument [Line Items]
Long-Term Debt [Table Text Block]	In March 2023, the Company issued $6.5 billion of senior unsecured notes consisting of the following: (in millions, except percentages) Par Value 4.250% notes due January 2029 $ 1,250 4.500% notes due April 2033 1,500 5.050% notes due April 2053 2,000 5.200% notes due April 2063 1,750

Dividends (Tables)

Dividends (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Dividends Declared	The following table provides details of the Company’s dividend payments during the six months ended June 30, 2023: Payment Date Amount per Share Total Amount Paid (in millions) March 21 $ 1.65 $ 1,537 June 27 1.88 1,747

Business Combinations (Tables)

Business Combinations (Tables)	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Acquired assets (liabilities) at acquisition date were: (in millions) Cash and cash equivalents $ 104 Accounts receivable and other current assets 550 Property, equipment and other long-term assets 542 Other intangible assets 1,795 Total identifiable assets acquired 2,991 Medical costs payable (1) Accounts payable and other current liabilities (473) Other long-term liabilities (617) Total identifiable liabilities acquired (1,091) Total net identifiable assets 1,900 Goodwill 7,734 Redeemable noncontrolling interests (113) Nonredeemable noncontrolling interests (1,297) Net assets acquired $ 8,224
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	The acquisition date fair values and weighted-average useful lives assigned to intangible assets were: (in millions, except years) Fair Value Weighted-Average Useful Life Acquired finite-lived intangible assets: Customer-related $ 223 12 years Trademarks and technology 171 5 years Other 38 6 years Total acquired finite-lived intangible assets 432 9 years Total acquired indefinite-lived intangible assets - operating licenses and certificates 1,363 Total acquired intangible assets $ 1,795

Segment Financial Information_2

Segment Financial Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following tables present reportable segment financial information: Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated Three Months Ended June 30, 2023 Revenues - unaffiliated customers: Premiums $ 67,047 $ 5,427 $ — $ — $ — $ 5,427 $ — $ 72,474 Products — 51 39 10,561 — 10,651 — 10,651 Services 2,584 3,541 1,995 543 — 6,079 — 8,663 Total revenues - unaffiliated customers 69,631 9,019 2,034 11,104 — 22,157 — 91,788 Total revenues - affiliated customers — 14,454 2,615 17,496 (893) 33,672 (33,672) — Investment and other income 600 444 25 46 — 515 — 1,115 Total revenues $ 70,231 $ 23,917 $ 4,674 $ 28,646 $ (893) $ 56,344 $ (33,672) $ 92,903 Earnings from operations $ 4,358 $ 1,525 $ 968 $ 1,206 $ — $ 3,699 $ — $ 8,057 Interest expense — — — — — — (828) (828) Earnings before income taxes $ 4,358 $ 1,525 $ 968 $ 1,206 $ — $ 3,699 $ (828) $ 7,229 Three Months Ended June 30, 2022 Revenues - unaffiliated customers: Premiums $ 59,368 $ 4,528 $ — $ — $ — $ 4,528 $ — $ 63,896 Products — 6 58 9,432 — 9,496 — 9,496 Services 2,542 2,740 1,034 329 — 4,103 — 6,645 Total revenues - unaffiliated customers 61,910 7,274 1,092 9,761 — 18,127 — 80,037 Total revenues - affiliated customers — 10,224 2,181 15,038 (588) 26,855 (26,855) — Investment and other income 195 85 9 6 — 100 — 295 Total revenues $ 62,105 $ 17,583 $ 3,282 $ 24,805 $ (588) $ 45,082 $ (26,855) $ 80,332 Earnings from operations $ 3,850 $ 1,399 $ 839 $ 1,044 $ — $ 3,282 $ — $ 7,132 Interest expense — — — — — — (467) (467) Earnings before income taxes $ 3,850 $ 1,399 $ 839 $ 1,044 $ — $ 3,282 $ (467) $ 6,665 Optum (in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum Eliminations Optum Corporate and Consolidated Six Months Ended June 30, 2023 Revenues - unaffiliated customers: Premiums $ 134,505 $ 10,755 $ — $ — $ — $ 10,755 $ — $ 145,260 Products — 95 79 20,744 — 20,918 — 20,918 Services 5,139 6,630 3,921 1,053 — 11,604 — 16,743 Total revenues - unaffiliated customers 139,644 17,480 4,000 21,797 — 43,277 — 182,921 Total revenues - affiliated customers — 28,720 5,125 34,175 (1,752) 66,268 (66,268) — Investment and other income 1,055 721 45 92 — 858 — 1,913 Total revenues $ 140,699 $ 46,921 $ 9,170 $ 56,064 $ (1,752) $ 110,403 $ (66,268) $ 184,834 Earnings from operations $ 8,701 $ 3,301 $ 1,875 $ 2,266 $ — $ 7,442 $ — $ 16,143 Interest expense — — — — — — (1,582) (1,582) Earnings before income taxes $ 8,701 $ 3,301 $ 1,875 $ 2,266 $ — $ 7,442 $ (1,582) $ 14,561 Six Months Ended June 30, 2022 Revenues - unaffiliated customers: Premiums $ 119,305 $ 8,661 $ — $ — $ — $ 8,661 $ — $ 127,966 Products — 12 98 18,726 — 18,836 — 18,836 Services 5,057 5,298 2,008 654 — 7,960 — 13,017 Total revenues - unaffiliated customers 124,362 13,971 2,106 19,380 — 35,457 — 159,819 Total revenues - affiliated customers — 20,053 4,319 29,329 (1,141) 52,560 (52,560) — Investment and other income 338 241 76 7 — 324 — 662 Total revenues $ 124,700 $ 34,265 $ 6,501 $ 48,716 $ (1,141) $ 88,341 $ (52,560) $ 160,481 Earnings from operations $ 7,648 $ 2,765 $ 1,686 $ 1,983 $ — $ 6,434 $ — $ 14,082 Interest expense — — — — — — (900) (900) Earnings before income taxes $ 7,648 $ 2,765 $ 1,686 $ 1,983 $ — $ 6,434 $ (900) $ 13,182

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Nature of Operations	UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary business platforms — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
Accounts Receivable, after Allowance for Credit Loss, Current	$ 17,952	$ 17,681
Revenue, Remaining Performance Obligation, Amount	$ 12,200
Revenue, Remaining Performance Obligation, Percentage	50%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	3 years
unh:ProductsandservicesMember
Accounts Receivable, after Allowance for Credit Loss, Current	$ 7,700	$ 7,100

Investments (Narrative) (Detail

Investments (Narrative) (Details) $ in Millions	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Investments [Abstract]
Equity Securities, FV-NI and without Readily Determinable Fair Value	$ 4,200	$ 3,700
Equity Method Investments	$ 1,400	$ 1,500
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions	35,000
Total number of security positions	41,000

Investments (Short-Term and Lon

Investments (Short-Term and Long-Term Investments) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	$ 47,558	$ 45,926
Securities, Available for sale Debt Securities, Gross Unrealized Gains	26	59
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(3,456)	(3,664)
Debt Securities, Available-for-sale	44,128	42,321
Held-to-maturity securities, Amortized Cost	740	696
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(14)	(17)
Debt Securities, Held-to-maturity, Fair Value	726	679
Total debt securities, Amortized Cost	48,298	46,622
Total debt securities, Gross Unrealized Gains	26	59
Total debt securities, Gross Unrealized Losses	(3,470)	(3,681)
Debt securities, Fair Value Disclosure	44,854	43,000
Debt Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale	44,128	42,321
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	4,990	4,093
Securities, Available for sale Debt Securities, Gross Unrealized Gains	0	1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(283)	(285)
Debt Securities, Available-for-sale	4,707	3,809
Held-to-maturity securities, Amortized Cost	466	578
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(11)	(14)
Debt Securities, Held-to-maturity, Fair Value	455	564
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	7,334	7,702
Securities, Available for sale Debt Securities, Gross Unrealized Gains	10	25
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(427)	(479)
Debt Securities, Available-for-sale	6,917	7,248
Held-to-maturity securities, Amortized Cost	28	29
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	(3)	(3)
Debt Securities, Held-to-maturity, Fair Value	25	26
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	23,582	23,675
Securities, Available for sale Debt Securities, Gross Unrealized Gains	11	17
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(1,643)	(1,798)
Debt Securities, Available-for-sale	21,950	21,894
Held-to-maturity securities, Amortized Cost	246	89
Securities, Held to maturity, Unrecognized Holding Gain	0	0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss	0	0
Debt Securities, Held-to-maturity, Fair Value	246	89
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	8,504	7,379
Securities, Available for sale Debt Securities, Gross Unrealized Gains	5	15
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(799)	(808)
Debt Securities, Available-for-sale	7,710	6,586
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Debt Securities, Available-for-sale, Amortized Cost	3,148	3,077
Securities, Available for sale Debt Securities, Gross Unrealized Gains	0	1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(304)	(294)
Debt Securities, Available-for-sale	$ 2,844	$ 2,784

Investments (Amortized Cost and

Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Due in one year or less, Amortized Cost	$ 4,646
Due after one year through five years, Amortized Cost	14,748
Due after five years through ten years, Amortized Cost	11,332
Due after ten years, Amortized Cost	5,180
Total debt securities - available-for-sale, Amortized Cost	47,558	$ 45,926
Due in one year or less, Fair Value	4,613
Due after one year through five years, Fair Value	13,935
Due after five years through ten years, Fair Value	10,206
Due after ten years, Fair Value	4,820
Debt Securities, Available-for-sale	44,128	42,321
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One	466
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five	225
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	31
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10	18
Debt Securities, Held-to-maturity	740	696
Held-to-maturity Securities, Debt Maturities, within One Year, Fair Value	461
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	219
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10	30
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10	16
Debt Securities, Held-to-maturity, Fair Value	726	679
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	8,504
Total debt securities - available-for-sale, Amortized Cost	8,504	7,379
Mortgage-backed securities, Fair Value	7,710
Debt Securities, Available-for-sale	7,710	6,586
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Mortgage-backed securities, Amortized Cost	3,148
Total debt securities - available-for-sale, Amortized Cost	3,148	3,077
Mortgage-backed securities, Fair Value	2,844
Debt Securities, Available-for-sale	$ 2,844	$ 2,784

Investments (Fair Value of Avai

Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Debt Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	$ 15,103	$ 24,899
Less Than 12 Months, Gross Unrealized Losses	(290)	(1,750)
Greater Than 12 Months, Fair Value	25,753	12,320
Greater Than 12 Months, Gross Unrealized Losses	(3,166)	(1,914)
Total, Fair Value	40,856	37,219
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(3,456)	(3,664)
U.S. Government and Agency Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	2,300	2,007
Less Than 12 Months, Gross Unrealized Losses	(28)	(96)
Greater Than 12 Months, Fair Value	1,902	1,290
Greater Than 12 Months, Gross Unrealized Losses	(255)	(189)
Total, Fair Value	4,202	3,297
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(283)	(285)
State and Municipal Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	2,769	4,630
Less Than 12 Months, Gross Unrealized Losses	(46)	(288)
Greater Than 12 Months, Fair Value	3,324	1,178
Greater Than 12 Months, Gross Unrealized Losses	(381)	(191)
Total, Fair Value	6,093	5,808
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(427)	(479)
Corporate Obligations [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	6,346	13,003
Less Than 12 Months, Gross Unrealized Losses	(122)	(893)
Greater Than 12 Months, Fair Value	13,974	6,637
Greater Than 12 Months, Gross Unrealized Losses	(1,521)	(905)
Total, Fair Value	20,320	19,640
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(1,643)	(1,798)
U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	3,111	3,561
Less Than 12 Months, Gross Unrealized Losses	(79)	(345)
Greater Than 12 Months, Fair Value	4,314	2,239
Greater Than 12 Months, Gross Unrealized Losses	(720)	(463)
Total, Fair Value	7,425	5,800
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	(799)	(808)
Non-U.S. Agency Mortgage-Backed Securities [Member]
Schedule of Investments [Line Items]
Less Than 12 Months, Fair Value	577	1,698
Less Than 12 Months, Gross Unrealized Losses	(15)	(128)
Greater Than 12 Months, Fair Value	2,239	976
Greater Than 12 Months, Gross Unrealized Losses	(289)	(166)
Total, Fair Value	2,816	2,674
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss	$ (304)	$ (294)

Fair Value (Narrative) (Details

Fair Value (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Fair Value [Line Items]
Transfers Into Level 3	$ 0	$ 0
Transfers out of Level 3	0	0
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis	$ 0	$ 0

Fair Value (Financial Assets an

Fair Value (Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 41,813	$ 23,365
Debt Securities, Available-for-sale	44,128	42,321
Equity Securities, FV-NI	2,377	2,148
Assets under management	3,623	4,087
Assets, Fair Value Disclosure	91,941	71,921
Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	44,128	42,321
U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,707	3,809
State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	6,917	7,248
Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	21,950	21,894
U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	7,710	6,586
Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	2,844	2,784
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	41,763	23,202
Equity Securities, FV-NI	2,270	2,043
Assets under management	1,332	1,788
Assets, Fair Value Disclosure	49,719	30,545
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,354	3,512
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	4,318	3,505
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	36	7
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	50	163
Equity Securities, FV-NI	37	35
Assets under management	2,190	2,203
Assets, Fair Value Disclosure	41,869	41,018
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	39,592	38,617
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	389	304
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	6,917	7,248
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	21,732	21,695
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	7,710	6,586
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	2,844	2,784
Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Equity Securities, FV-NI	70	70
Assets under management	101	96
Assets, Fair Value Disclosure	353	358
Unobservable Inputs (Level 3) [Member] | Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	182	192
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	182	192
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0	0
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 0	$ 0

Fair Value (Financial Assets _2

Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	$ 726	$ 679
Debt Securities, Held-to-maturity	740	696
Fair Value, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	726	679
Debt and other financing obligations	58,644	53,626
Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	651	577
Debt and other financing obligations	0	0
Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	75	102
Debt and other financing obligations	58,644	53,626
Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Held-to-maturity, Fair Value	0	0
Debt and other financing obligations	0	0
Long-term debt and other financing obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt and other financing obligations, carrying value	$ 61,217	$ 56,823

Medical Costs Payable (Narrativ

Medical Costs Payable (Narrative) (Details) - USD ($) $ in Billions	Jun. 30, 2023	Dec. 31, 2022
Insurance [Abstract]
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount	$ 22	$ 20

Medical Costs Payable (Details)

Medical Costs Payable (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]
Medical costs payable, beginning of period	$ 29,056	$ 24,483
Acquisitions	1	171
Reported medical costs:
Current year	120,773	104,936
Prior year	(660)	(320)
Total reported medical costs	120,113	104,616
Medical payments:
Payments for current year	(91,621)	(78,937)
Payments for prior years	(25,602)	(21,355)
Total medical payments	(117,223)	(100,292)
Medical costs payable, end of period	$ 31,947	$ 28,978

Short-Term Borrowings and Lon_3

Short-Term Borrowings and Long-Term Debt (Details) $ in Millions	Mar. 31, 2023 USD ($)
Debt Instrument [Line Items]
Par Value	$ 6,500
4.250% notes due January 2029
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Par Value	$ 1,250
4.500% notes due April 2033
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Par Value	$ 1,500
5.050% notes due April 2053
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.05%
Par Value	$ 2,000
5.200% notes due April 2063
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	5.20%
Par Value	$ 1,750

Short-Term Borrowings and Lon_4

Short-Term Borrowings and Long-Term Debt (Narrative) (Details) $ in Millions	Jun. 30, 2023 USD ($) Rate
Debt Instrument [Line Items]
Commercial Paper | $	$ 4,400
Commercial Paper [Member]
Debt Instrument [Line Items]
Short-term Debt, Weighted Average Interest Rate, at Point in Time | Rate	5.10%

Dividends (Details)

Dividends (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended		6 Months Ended
	Jun. 27, 2023	Mar. 21, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Equity [Abstract]
Common Stock, Dividends, Per Share, Cash Paid	$ 1.88	$ 1.65	$ 1.88	$ 1.65	$ 3.53	$ 3.10
Payments of Ordinary Dividends, Common Stock	$ 1,747	$ 1,537			$ 3,284	$ 2,908

Commitments and Contingencies_2

Commitments and Contingencies (Details) $ in Billions	6 Months Ended
	Jun. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Other Commitments, Description	As of June 30, 2023, the Company has entered into agreements to acquire companies in the health care sector, subject to regulatory approval and other customary closing conditions.
Other Commitment	$ 5

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Business Combination and Asset Acquisition [Abstract]
Business Combination, Consideration Transferred	$ 8,200

Business Combinations (Details)

Business Combinations (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Business Acquisition [Line Items]
Cash and cash equivalents	$ 104
Accounts receivable and other current assets	550
Property, equipment and other long-term assets	542
Other Intangible Assets	1,795
Total identifiable assets acquired	2,991
Medical costs payable	(1)
Accounts payable and other current liabilities	(473)
Other long-term liabilities	(617)
Total identifiable liabilities acquired	(1,091)
Total net tangible assets	1,900
Goodwill	7,734
Redeemable noncontrolling interests	(113)
Nonredeemable noncontrolling interests	(1,297)
Net Assets Acquired	$ 8,224

Business Combinations Acquired

Business Combinations Acquired Finite-Lived Intangible Asets (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 432
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	9 years
Indefinite-Lived Intangible Assets Acquired	$ 1,363
Other Intangible Assets	1,795
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 223
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	12 years
Trademarks and Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 171
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	5 years
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 38
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	6 years

Segment Financial Information_3

Segment Financial Information (Narrative) (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) reportableSegments	Dec. 31, 2022 USD ($)
Statement [Line Items]
Number of Reportable Segments | reportableSegments	4
Assets	$ 280,164	$ 245,705
Goodwill	7,734
Optum Health
Statement [Line Items]
Assets	80,800	$ 69,000
Goodwill	$ 7,000

Segment Financial Information_4

Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement [Line Items]
Premiums, revenues - unaffiliated customers	$ 72,474	$ 63,896	$ 145,260	$ 127,966
Investment and other income	1,115	295	1,913	662
Total revenues	92,903	80,332	184,834	160,481
Earnings from operations	8,057	7,132	16,143	14,082
Interest expense	(828)	(467)	(1,582)	(900)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	7,229	6,665	14,561	13,182
Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,651	9,496	20,918	18,836
Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	8,663	6,645	16,743	13,017
Optum
Statement [Line Items]
Investment and other income	515	100	858	324
Total revenues	56,344	45,082	110,403	88,341
Earnings from operations	3,699	3,282	7,442	6,434
Interest expense	0	0	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	3,699	3,282	7,442	6,434
Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	72,474	63,896	145,260	127,966
Total revenues	91,788	80,037	182,921	159,819
Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,651	9,496	20,918	18,836
Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	8,663	6,645	16,743	13,017
Unaffiliated Customers | Optum
Statement [Line Items]
Premiums, revenues - unaffiliated customers	5,427	4,528	10,755	8,661
Total revenues	22,157	18,127	43,277	35,457
Unaffiliated Customers | Optum | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,651	9,496	20,918	18,836
Unaffiliated Customers | Optum | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	6,079	4,103	11,604	7,960
Affiliated Customers
Statement [Line Items]
Total revenues	0	0	0	0
Affiliated Customers | Optum
Statement [Line Items]
Total revenues	33,672	26,855	66,268	52,560
Operating Segments | UnitedHealthcare
Statement [Line Items]
Investment and other income	600	195	1,055	338
Total revenues	70,231	62,105	140,699	124,700
Earnings from operations	4,358	3,850	8,701	7,648
Interest expense	0	0	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	4,358	3,850	8,701	7,648
Operating Segments | Optum Health
Statement [Line Items]
Investment and other income	444	85	721	241
Total revenues	23,917	17,583	46,921	34,265
Earnings from operations	1,525	1,399	3,301	2,765
Interest expense	0	0	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	1,525	1,399	3,301	2,765
Operating Segments | Optum Insight
Statement [Line Items]
Investment and other income	25	9	45	76
Total revenues	4,674	3,282	9,170	6,501
Earnings from operations	968	839	1,875	1,686
Interest expense	0	0	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	968	839	1,875	1,686
Operating Segments | Optum Rx
Statement [Line Items]
Investment and other income	46	6	92	7
Total revenues	28,646	24,805	56,064	48,716
Earnings from operations	1,206	1,044	2,266	1,983
Interest expense	0	0	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	1,206	1,044	2,266	1,983
Operating Segments | Unaffiliated Customers | UnitedHealthcare
Statement [Line Items]
Premiums, revenues - unaffiliated customers	67,047	59,368	134,505	119,305
Total revenues	69,631	61,910	139,644	124,362
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0	0
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	2,584	2,542	5,139	5,057
Operating Segments | Unaffiliated Customers | Optum Health
Statement [Line Items]
Premiums, revenues - unaffiliated customers	5,427	4,528	10,755	8,661
Total revenues	9,019	7,274	17,480	13,971
Operating Segments | Unaffiliated Customers | Optum Health | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	51	6	95	12
Operating Segments | Unaffiliated Customers | Optum Health | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	3,541	2,740	6,630	5,298
Operating Segments | Unaffiliated Customers | Optum Insight
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0	0
Total revenues	2,034	1,092	4,000	2,106
Operating Segments | Unaffiliated Customers | Optum Insight | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	39	58	79	98
Operating Segments | Unaffiliated Customers | Optum Insight | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	1,995	1,034	3,921	2,008
Operating Segments | Unaffiliated Customers | Optum Rx
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0	0
Total revenues	11,104	9,761	21,797	19,380
Operating Segments | Unaffiliated Customers | Optum Rx | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	10,561	9,432	20,744	18,726
Operating Segments | Unaffiliated Customers | Optum Rx | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	543	329	1,053	654
Operating Segments | Affiliated Customers | UnitedHealthcare
Statement [Line Items]
Total revenues	0	0	0	0
Operating Segments | Affiliated Customers | Optum Health
Statement [Line Items]
Total revenues	14,454	10,224	28,720	20,053
Operating Segments | Affiliated Customers | Optum Insight
Statement [Line Items]
Total revenues	2,615	2,181	5,125	4,319
Operating Segments | Affiliated Customers | Optum Rx
Statement [Line Items]
Total revenues	17,496	15,038	34,175	29,329
Optum Eliminations
Statement [Line Items]
Investment and other income	0	0	0	0
Total revenues	(893)	(588)	(1,752)	(1,141)
Earnings from operations	0	0	0	0
Interest expense	0	0	0	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	0	0	0	0
Optum Eliminations | Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0	0
Total revenues	0	0	0	0
Optum Eliminations | Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0	0
Optum Eliminations | Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0	0
Optum Eliminations | Affiliated Customers
Statement [Line Items]
Total revenues	(893)	(588)	(1,752)	(1,141)
Corporate and Eliminations
Statement [Line Items]
Investment and other income	0	0	0	0
Total revenues	(33,672)	(26,855)	(66,268)	(52,560)
Earnings from operations	0	0	0	0
Interest expense	(828)	(467)	(1,582)	(900)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	(828)	(467)	(1,582)	(900)
Corporate and Eliminations | Unaffiliated Customers
Statement [Line Items]
Premiums, revenues - unaffiliated customers	0	0	0	0
Total revenues	0	0	0	0
Corporate and Eliminations | Unaffiliated Customers | Products
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0	0
Corporate and Eliminations | Unaffiliated Customers | Services
Statement [Line Items]
Revenue from Products and Services - unaffiliated customers	0	0	0	0
Corporate and Eliminations | Affiliated Customers
Statement [Line Items]
Total revenues	$ (33,672)	$ (26,855)	$ (66,268)	$ (52,560)